Femme et Homme
- | Pays :
- Finland
- | Organes : -
- | Spécialités : -
Extrait
This single arm study will assess the safety and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current non-biologic DMARDs. Patients will receive iv infusions of tocilizumab 8mg/kg every 4 weeks for a total of 6 infusions, either as monotherapy or in combination with their current non-biologic DMARDs.
Critère d'inclusion
- Rheumatoid Arthritis